C. Ellen van der Schoot

24.6k total citations · 1 hit paper
332 papers, 11.5k citations indexed

About

C. Ellen van der Schoot is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, C. Ellen van der Schoot has authored 332 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 209 papers in Hematology, 72 papers in Immunology and 60 papers in Molecular Biology. Recurrent topics in C. Ellen van der Schoot's work include Blood groups and transfusion (141 papers), Platelet Disorders and Treatments (67 papers) and Erythrocyte Function and Pathophysiology (53 papers). C. Ellen van der Schoot is often cited by papers focused on Blood groups and transfusion (141 papers), Platelet Disorders and Treatments (67 papers) and Erythrocyte Function and Pathophysiology (53 papers). C. Ellen van der Schoot collaborates with scholars based in Netherlands, United Kingdom and Germany. C. Ellen van der Schoot's co-authors include Masja de Haas, A. E. G. Kr. von dem Borne, Carlijn Voermans, Gestur Vidarsson, Joke M. Koelewijn, Jacques J. M. van Dongen, Petra A. Maaskant‐van Wijk, Peter C. Ligthart, Marion Kleijer and Vincent H. J. van der Velden and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

C. Ellen van der Schoot

323 papers receiving 11.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

2003 656 citations Vincent H. J. van der Velden, C. Ellen van der Schoot et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Ellen van der Schoot Netherlands	57	5.9k	2.8k	2.4k	2.0k	2.0k	332	11.5k
Masja de Haas Netherlands	56	4.9k 0.8×	1.9k 0.7×	3.2k 1.3×	1.4k 0.7×	1.4k 0.7×	275	9.8k
James S. Wainscoat United Kingdom	46	2.9k 0.5×	5.1k 1.8×	1.6k 0.7×	3.6k 1.8×	1.9k 1.0×	134	13.1k
Kristen E. Stevenson United States	35	3.4k 0.6×	1.9k 0.7×	1.3k 0.5×	1.1k 0.5×	1.3k 0.7×	128	7.2k
Mitchell S. Cairo United States	61	4.8k 0.8×	2.7k 1.0×	3.0k 1.2×	2.8k 1.4×	2.6k 1.3×	507	14.9k
Charlotte M. Niemeyer Germany	54	4.8k 0.8×	4.1k 1.5×	2.1k 0.9×	976 0.5×	1.8k 0.9×	260	10.3k
David C. Linch United Kingdom	74	8.9k 1.5×	4.8k 1.7×	3.7k 1.5×	790 0.4×	4.9k 2.5×	358	20.9k
Nelson J. Chao United States	54	5.4k 0.9×	2.1k 0.7×	3.6k 1.5×	476 0.2×	1.7k 0.9×	337	11.0k
Richard Childs United States	57	4.6k 0.8×	2.3k 0.8×	4.6k 1.9×	574 0.3×	1.5k 0.8×	273	10.7k
Peter Vandenberghe Belgium	58	2.3k 0.4×	3.1k 1.1×	2.7k 1.1×	322 0.2×	1.6k 0.8×	229	10.7k
Anneke Brand Netherlands	55	5.4k 0.9×	604 0.2×	2.3k 0.9×	854 0.4×	1.4k 0.7×	291	11.0k

Countries citing papers authored by C. Ellen van der Schoot

Since Specialization

Citations

This map shows the geographic impact of C. Ellen van der Schoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Ellen van der Schoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Ellen van der Schoot more than expected).

Fields of papers citing papers by C. Ellen van der Schoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Ellen van der Schoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Ellen van der Schoot. The network helps show where C. Ellen van der Schoot may publish in the future.

Co-authorship network of co-authors of C. Ellen van der Schoot

This figure shows the co-authorship network connecting the top 25 collaborators of C. Ellen van der Schoot. A scholar is included among the top collaborators of C. Ellen van der Schoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Ellen van der Schoot. C. Ellen van der Schoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Clausen, Frederik Banch & C. Ellen van der Schoot. (2025). Noninvasive fetal blood group antigen genotyping.. PubMed. 23(2). 101–108. 2 indexed citations

Bentlage, Arthur E. H., José M. de Pereda, Leendert Porcelijn, et al.. (2025). HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins. Blood. 146(18). 2189–2202.

Folman, Claudia C., et al.. (2024). Major reduction in occurrence of anti‐c and anti‐E in pregnancy after more than 10 years of preventive matched transfusion with most benefit for c‐matching. British Journal of Haematology. 205(4). 1599–1604. 3 indexed citations

Porcelijn, Leendert, Camila Caram‐Deelder, Jonathan M. Coutinho, et al.. (2024). Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients. Antibodies. 13(2). 35–35.

Linty, Federica, Remco Visser, Leendert Porcelijn, et al.. (2024). Generation of human antibodies targeting human platelet antigen (HPA)‐1a. Transfusion. 64(5). 893–905. 1 indexed citations

Stutterheim, Janine, Hester A. de Groot‐Kruseman, Edwin Sonneveld, et al.. (2024). Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?. Leukemia. 38(11). 2376–2381. 2 indexed citations

Porcelijn, Leendert, Yvonne Henskens, Jonathan M. Coutinho, et al.. (2024). Laboratory approach for vaccine‐induced thrombotic thrombocytopenia diagnosis in the Netherlands. Vox Sanguinis. 119(7). 728–736. 3 indexed citations

Lopriore, Enrico, Dick Oepkes, Leendert Porcelijn, et al.. (2024). Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost–utility analysis. Vox Sanguinis. 120(2). 178–187. 2 indexed citations

Velden, Saskia van der, Arthur E. H. Bentlage, Juk Yee Mok, et al.. (2023). Complement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs. Blood. 143(1). 79–91. 19 indexed citations

10.

Bruggen, Robin van, Anja ten Brinke, Sanne de Bruin, et al.. (2022). Measurement of post‐transfusion red blood cell survival kinetics in sickle cell disease and β‐Thalassemia: A biotin label approach. Transfusion. 62(10). 1984–1996. 5 indexed citations

11.

Bentlage, Arthur E. H., Jan Nouta, Carolien A. M. Koeleman, et al.. (2022). Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets. Haematologica. 107(10). 2432–2444. 23 indexed citations

12.

Winkelhorst, Dian, Hans J. Baelde, Lotte E. van der Meeren, et al.. (2021). Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study. International Journal of Molecular Sciences. 22(13). 6763–6763. 10 indexed citations

13.

Zappeij‐Kannegieter, Lily, Lieke M. J. van Zogchel, Marta Fiocco, et al.. (2021). Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease. Clinical Cancer Research. 27(20). 5576–5585. 11 indexed citations

14.

Bovenkamp, Fleur S. van de, Ninotska I. L. Derksen, Pleuni Ooijevaar‐de Heer, et al.. (2018). Adaptive antibody diversification through N -linked glycosylation of the immunoglobulin variable region. Proceedings of the National Academy of Sciences. 115(8). 1901–1906. 99 indexed citations

15.

Kraal, Kathelijne C.J.M., Ilse Timmerman, Cor van den Bos, et al.. (2018). Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution. Clinical Cancer Research. 25(3). 1012–1021. 5 indexed citations

16.

Klamer, Sofieke, Marion Kleijer, Dirk Geerts, et al.. (2018). TGFBI Expressed by Bone Marrow Niche Cells and Hematopoietic Stem and Progenitor Cells Regulates Hematopoiesis. Stem Cells and Development. 27(21). 1494–1506. 12 indexed citations

17.

Sonneveld, Myrthe E., Masja de Haas, Carolien A. M. Koeleman, et al.. (2017). Patients with IgG1-anti-red blood cell autoantibodies show aberrant Fc-glycosylation. Scientific Reports. 7(1). 8187–8187. 24 indexed citations

18.

Maijenburg, Marijke W., Christian Gilissen, Marion Kleijer, et al.. (2016). Different Balance of Wnt Signaling in Adult and Fetal Bone Marrow-Derived Mesenchymal Stromal Cells. Stem Cells and Development. 25(12). 934–947. 8 indexed citations

19.

Maijenburg, Marijke W., Christian Gilissen, Sara M. Melief, et al.. (2011). Nuclear Receptors Nur77 and Nurr1 Modulate Mesenchymal Stromal Cell Migration. Stem Cells and Development. 21(2). 228–238. 56 indexed citations

20.

Stutterheim, Janine, et al.. (2011). Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma. Clinical Cancer Research. 18(3). 808–814. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact